IGC Pharma (IGC) Stock: Insider Trades, Congress & Funds

Smart money at a glance

Filings to Nov 9, 2026

No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersForm 4, 90 days: $0
CongressSTOCK Act, 180 days: None
Big funds13F, latest quarter: No large changes

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

Unlock the full results

Questions about IGC filings

Are insiders buying or selling IGC Pharma, Inc. (IGC) stock?

Neither. IGC Pharma, Inc. (IGC) insiders filed no open-market purchases or sales in the 90 days to Nov 9, 2026, according to SEC Form 4 filings.

Which members of Congress have traded IGC recently?

None. No member of Congress disclosed a IGC trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this IGC smart-money data?

This summary uses filings available on Nov 9, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.

No recent filings found.

Questions about IGC filings

Are insiders buying or selling IGC Pharma, Inc. (IGC) stock?

Neither. IGC Pharma, Inc. (IGC) insiders filed no open-market purchases or sales in the 90 days to Nov 9, 2026, according to SEC Form 4 filings.

Which members of Congress have traded IGC recently?

None. No member of Congress disclosed a IGC trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this IGC smart-money data?

Checking federal contract awards

Unlock everything for $29/month

Unlock for $29/month

Reported Nov 6, 2026

Earnings landed in line with what analysts expected.

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Nov 6, 2026

Period ending

Sep 30, 2026

Earnings per share

-$0.02+$0.00 in line

-$0.02 expected

Revenue

$328.0K

Yahoo Finance

EPS and revenue: Yahoo Finance

Next report

Estimated report: Nov 13, 2026, in 4 days

Previous reports

Quarter / reported	Earnings per share	Beat or miss	Revenue / income	Revenue vs last year
Sep 30, 2026Reported Nov 6, 2026	-$0.02est. -$0.02	+$0.00in line	$328.0KYahoo Finance	+71.7%from $191.0K
Jun 30, 2026Reported Aug 14, 2026	-$0.03est. -$0.02	-$0.01miss	$265.0KSEC filing	-19.2%from $328.0K
Mar 31, 2026Reported May 15, 2026	-$0.02est. -$0.02	+$0.00in line	$317.0KSEC filing	-3.9%from $330.0K
Dec 31, 2025Reported Feb 18, 2026	-$0.02est. -$0.02	+$0.00in line	Not on file	Not on file
Sep 30, 2025Reported Nov 14, 2025	-$0.02est. -$0.02	+$0.00in line	$191.0KSEC filing	-53.6%from $412.0K
Jun 30, 2025Reported Aug 14, 2025	-$0.01est. -$0.03	+$0.02beat	$328.0KSEC filing	+20.6%from $272.0K
Mar 31, 2025Reported Jun 27, 2025	-$0.01est. -$0.02	+$0.01beat	$330.0KSEC filing	No year-ago quarter
Dec 31, 2024Reported Feb 14, 2025	-$0.02est. -$0.03	+$0.01beat	$257.0KSEC filing	+26.0%from $204.0K

Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.

Open: $0.19
High: $0.20
Low: $0.18
Prev close: $0.19
52-wk high: $0.40
52-wk low: $0.18
Mkt cap: $20.7M
ROE: -83.3%
Beta: 0.55
P/S: 18.7x
P/B: 3.4x
Profit margin: +0.0%
Op margin: -1051.0%

Fundamentals

Is the business strong?

This company is running thin margins.

Net margin: 0.0%
Market cap: $21M

Valuation

P/S18.70
P/B3.37

Quality

Operating margin-1051.0%
ROE-83.3%
ROA-50.3%

Growth

Beta0.55

Technicals

Price structure

This stock is under pressure.

Trend

Under pressure

0 / 100

RSI 14

33balanced

20D volatility

82%annualized

52-week range

$0.20

$0.18$0.40

20D support

$0.08recent floor

20D resistance

$0.28recent ceiling

Returns

5D +8.1%20D -28.5%60D -32.0%

Price vs moving averages

SMA20 -13.0%SMA50 -23.5%SMA200 -27.8%

Volume pace

0.80xvs prior 20D

Smart money at a glance

Filings to Nov 9, 2026

No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersForm 4, 90 days: $0
CongressSTOCK Act, 180 days: None
Big funds13F, latest quarter: No large changes

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

Unlock the full results

Questions about IGC filings

Are insiders buying or selling IGC Pharma, Inc. (IGC) stock?

Neither. IGC Pharma, Inc. (IGC) insiders filed no open-market purchases or sales in the 90 days to Nov 9, 2026, according to SEC Form 4 filings.

Which members of Congress have traded IGC recently?

None. No member of Congress disclosed a IGC trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this IGC smart-money data?

No recent filings found.

Questions about IGC filings

Are insiders buying or selling IGC Pharma, Inc. (IGC) stock?

Neither. IGC Pharma, Inc. (IGC) insiders filed no open-market purchases or sales in the 90 days to Nov 9, 2026, according to SEC Form 4 filings.

Which members of Congress have traded IGC recently?

None. No member of Congress disclosed a IGC trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this IGC smart-money data?

Checking federal contract awards

Unlock everything for $29/month

Unlock for $29/month

Reported Nov 6, 2026

Earnings landed in line with what analysts expected.

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Nov 6, 2026

Period ending

Sep 30, 2026

Earnings per share

-$0.02+$0.00 in line

-$0.02 expected

Revenue

$328.0K

Yahoo Finance

EPS and revenue: Yahoo Finance

Next report

Estimated report: Nov 13, 2026, in 4 days

Previous reports

Quarter / reported	Earnings per share	Beat or miss	Revenue / income	Revenue vs last year
Sep 30, 2026Reported Nov 6, 2026	-$0.02est. -$0.02	+$0.00in line	$328.0KYahoo Finance	+71.7%from $191.0K
Jun 30, 2026Reported Aug 14, 2026	-$0.03est. -$0.02	-$0.01miss	$265.0KSEC filing	-19.2%from $328.0K
Mar 31, 2026Reported May 15, 2026	-$0.02est. -$0.02	+$0.00in line	$317.0KSEC filing	-3.9%from $330.0K
Dec 31, 2025Reported Feb 18, 2026	-$0.02est. -$0.02	+$0.00in line	Not on file	Not on file
Sep 30, 2025Reported Nov 14, 2025	-$0.02est. -$0.02	+$0.00in line	$191.0KSEC filing	-53.6%from $412.0K
Jun 30, 2025Reported Aug 14, 2025	-$0.01est. -$0.03	+$0.02beat	$328.0KSEC filing	+20.6%from $272.0K
Mar 31, 2025Reported Jun 27, 2025	-$0.01est. -$0.02	+$0.01beat	$330.0KSEC filing	No year-ago quarter
Dec 31, 2024Reported Feb 14, 2025	-$0.02est. -$0.03	+$0.01beat	$257.0KSEC filing	+26.0%from $204.0K

Open: $0.19
High: $0.20
Low: $0.18
Prev close: $0.19
52-wk high: $0.40
52-wk low: $0.18
Mkt cap: $20.7M
ROE: -83.3%
Beta: 0.55
P/S: 18.7x
P/B: 3.4x
Profit margin: +0.0%
Op margin: -1051.0%

Fundamentals

Is the business strong?

This company is running thin margins.

Net margin: 0.0%
Market cap: $21M

Valuation

P/S18.70
P/B3.37

Quality

Operating margin-1051.0%
ROE-83.3%
ROA-50.3%

Growth

Beta0.55

Technicals

Price structure

This stock is under pressure.

Trend

Under pressure

0 / 100

RSI 14

33balanced

20D volatility

82%annualized

52-week range

$0.20

$0.18$0.40

20D support

$0.08recent floor

20D resistance

$0.28recent ceiling

Returns

5D +8.1%20D -28.5%60D -32.0%

Price vs moving averages

SMA20 -13.0%SMA50 -23.5%SMA200 -27.8%

Volume pace

0.80xvs prior 20D

IGC Pharma, Inc.

Smart money at a glance

What do analysts expect?

Questions about IGC filings

Questions about IGC filings

How top traders are positioned

Unlock everything for $29/month

Earnings landed in line with what analysts expected.

Estimated report: Nov 13, 2026, in 4 days

Previous reports

Is the business strong?

Price structure

Ask it in Claude or ChatGPT.

IGC Pharma, Inc.

Smart money at a glance

What do analysts expect?

Questions about IGC filings

Questions about IGC filings

How top traders are positioned

Unlock everything for $29/month

Earnings landed in line with what analysts expected.

Estimated report: Nov 13, 2026, in 4 days

Previous reports

Is the business strong?

Price structure

Ask it in Claude or ChatGPT.

IGC Pharma, Inc.

Overview

Questions about IGC filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.

IGC Pharma, Inc.

Overview

Questions about IGC filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.